Meeting
2022 ASCO Annual Meeting
Association of proton pump inhibitor use with survival outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Authors
BaoQing Chen
Sun Yat-sen University Cancer Center, Guangzhou, China
BaoQing Chen , Chen Yang , Mihnea-Paul Dragomir , Dongmei Chi , Wenyan Chen , George Calin , Qiaoqiao Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2613)
DOI
10.1200/JCO.2022.40.16_suppl.2613
Abstract #
2613
Poster Bd #
268
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2022 ASCO Annual Meeting
Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.
First Author: Gerard Zalcman
Poster
2024 ASCO Annual Meeting
Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Charbel Hobeika
Poster
2021 ASCO Annual Meeting
Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.
First Author: Marium Husain